SCSeoyoon Choi

Seoyoon Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seoyoon Choi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nationwide Analysis of Eye-Related Emergency Department Visits in South Korea: NEDIS-EYE REPORT 1

    by Richul Oh, Seoyoon Choi, Kyu Hyung Park, Sang Jun Park

    To analyze the diagnosis of eye-related emergency department (ED) visits in South Korea and to investigate the national burden of eye-related visits in the ED and their trends over time. Data were obtained from the National Emergency Department Information System in South Korea between 2014 and 2022. A total of 74,714,270 ED visits were analyzed. Eye-related ED visits were identified using diagnosis codes at the time of discharge from ED. Temporal trends in annual ED visits were analyzed. Eye-related ED visits were categorized into three groups based on the emergent categories (emergent, unlikely-emergent, and indeterminate). During the 9-year study period, eye-related ED visits accounted for 1,356,169 (1.82%) visits. Total ED visits significantly decreased in 2020 due to the COVID-19 pandemic, with a partial recovery by 2022 to 85% of 2019 levels. The number of eye-related ED visits similarly decreased in 2020, but it continued to decline until 2022, with its proportion dropping from 2.08% in 2014 to 1.58% in 2022 (rate: -0.0547%/year, 95% confidence interval: [-0.0723, -0.0371], p < 0.001). The SIR of total ED visits declined by 6.12% from 2014 to 2022. Among the eye-related ED visits, there were emergent (19.7%), unlikely-emergent (13.2%), and indeterminate (67.1%) cases. Eye-related ED visits in South Korea decreased over the 9-year study period and the proportion of emergent cases increased. The steady decline in eye-related ED visits, along with an increase in emergent cases, may have implications for the allocation of ED resources in the field of ophthalmology.

  • Open Access

    Long-term economc burden and related influencing factors of pediatric cataracst: A population-based study in South Korea

    by Semin Jang, Sang Jun Park, Seo Yoon Choi, Migyeong Jeong, Siin Kim, Hae Sun Suh

    Pediatric cataracts are a significant cause of childhood blindness, requiring long-term management. This study evaluated the economic burden of pediatric cataract surgery in South Korea and identified factors influencing the medical costs, particularly in patients with complications after cataract surgery. We used National Health Insurance Service claims data, covering the Korean population, including pediatric patients (aged ≤5 years) who underwent cataract surgery between 2004 and 2011. We measured healthcare resource utilization (outpatient, inpatient, and emergency department visits) and cataract-related medical costs over an 8-year follow-up after cataract surgery. We further explored factors influencing medical costs using a generalized linear model. A total of 1297 pediatric patients (mean age: 2.2 years, 56.8% male) were included. Over 8 years, patients had an average of 30 outpatient visits, 2.7 inpatient visits, and 3 emergency department visits. The total average medical cost over 8 years was $2,391 per patient, with significantly higher costs in those developed retinal detachment ($7729) or glaucoma ($8,821) developed after the surgery. Additionally, higher costs were associated with older age at surgery, higher income, the presence of postoperative complications, and multiple surgeries. Pediatric cataract surgery resulted in a considerable long-term economic burden, particularly when accompanied by postoperative complications. This study provides real-world evidence underscoring the need for improvement in pediatric cataract management to ensure optimal care for young patients at risk of vision impairment.

  • Open Access

    Analysis of Retinal Thickness in Patients With Chronic Diseases Using Standardized Optical Coherence Tomography Data: Database Study Based on the Radiology Common Data Model

    by ChulHyoung Park, So Hee Lee, Da Yun Lee, Seoyoon Choi, Seng Chan You, Ja Young Jeon, Sang Jun Park, Rae Woong Park

    Background: The Observational Medical Outcome Partners-Common Data Model (OMOP-CDM) is an international standard for harmonizing electronic medical record (EMR) data. However, since it does not standardize unstructured data, such as medical imaging, using this data in multi-institutional collaborative research becomes challenging. To overcome this limitation, extensions such as the Radiology Common Data Model (R-CDM) have emerged to include and standardize these data types. Objective: This work aims to demonstrate that by standardizing optical coherence tomography (OCT) data into an R-CDM format, multi-institutional collaborative studies analyzing changes in retinal thickness in patients with long-standing chronic diseases can be performed efficiently. Methods: We standardized OCT images collected from two tertiary hospitals for research purposes using the R-CDM. As a proof of concept, we conducted a comparative analysis of retinal thickness between patients who have chronic diseases and those who have not. Patients diagnosed or treated for retinal and choroidal diseases, which could affect retinal thickness, were excluded from the analysis. Using the existing OMOP-CDM at each institution, we extracted cohorts of patients with chronic diseases and control groups, performing large-scale 1:2 propensity score matching (PSM). Subsequently, we linked the OMOP-CDM and R-CDM to extract the OCT image data of these cohorts and analyzed central macular thickness (CMT) and retinal nerve fiber layer (RNFL) thickness using a linear mixed model. Results: OCT data of 261,874 images from Ajou University Medical Center (AUMC) and 475,626 images from Seoul National University Bundang Hospital (SNUBH) were standardized in the R-CDM format. The R-CDM databases established at each institution were linked with the OMOP-CDM database. Following 1:2 PSM, the type 2 diabetes mellitus (T2DM) cohort included 957 patients, and the control cohort had 1603 patients. During the follow-up period, significant reductions in CMT were observed in the T2DM cohorts at AUMC (P=.04) and SNUBH (P=.007), without significant changes in RNFL thickness (AUMC: P=.56; SNUBH: P=.39). Notably, a significant reduction in CMT during the follow-up was observed only at AUMC in the hypertension cohort, compared to the control group (P=.04); no other significant differences in retinal thickness were found in the remaining analyses. Conclusions: The significance of our study lies in demonstrating the efficiency of multi-institutional collaborative research that simultaneously uses clinical data and medical imaging data by leveraging the OMOP-CDM for standardizing EMR data and the R-CDM for standardizing medical imaging data.


  • Open Access

    Patient-Centered Economic Burden of Diabetic Macular Edema: Retrospective Cohort Study

    by Kyungseon Choi, Sang Jun Park, Hyuna Yoon, Seoyoon Choi, Yongseok Mun, Seok Kim, Sooyoung Yoo, Se Joon Woo, Kyu Hyung Park, Junghyun Na, et al.

    Background: Diabetic macular edema (DME), a leading cause of blindness, requires treatment with costly drugs, such as anti–vascular endothelial growth factor (VEGF) agents. The prolonged use of these effective but expensive drugs results in an incremental economic burden for patients with DME compared with those with diabetes mellitus (DM) without DME. However, there are no studies on the long-term patient-centered economic burden of DME after reimbursement for anti-VEGFs. Objective: This retrospective cohort study aims to estimate the 3-year patient-centered economic burden of DME compared with DM without DME, using the Common Data Model. Methods: We used medical data from 1,903,603 patients (2003-2020), transformed and validated using the Observational Medical Outcomes Partnership Common Data Model from Seoul National University Bundang Hospital. We defined the group with DME as patients aged >18 years with nonproliferative diabetic retinopathy and intravitreal anti-VEGF or steroid prescriptions. As control, we defined the group with DM without DME as patients aged >18 years with DM or diabetic retinopathy without intravitreal anti-VEGF or steroid prescriptions. Propensity score matching, performed using a regularized logistic regression with a Laplace prior, addressed selection bias. We estimated direct medical costs over 3 years categorized into total costs, reimbursement costs, nonreimbursement costs, out-of-pocket costs, and costs covered by insurance, as well as healthcare resource utilization. An exponential conditional model and a count model estimated unbiased incremental patient-centered economic burden using generalized linear models and a zero-inflation model. Results: In a cohort of 454 patients with DME matched with 1640 patients with DM, the economic burden of DME was significantly higher than that of DM, with total costs over 3 years being 2.09 (95% CI 1.78-2.47) times higher. Reimbursement costs were 1.89 (95% CI 1.57-2.28) times higher in the group with DME than with the group with DM, while nonreimbursement costs were 2.54 (95% CI 2.12-3.06) times higher. Out-of-pocket costs and costs covered by insurance were also higher by a factor of 2.11 (95% CI 1.58-2.59) and a factor of 2.01 (95% CI 1.85-2.42), respectively. Patients with DME had a significantly higher number of outpatient (1.87-fold) and inpatient (1.99-fold) visits compared with those with DM (P<.001 in all cases). Conclusions: Patients with DME experience a heightened economic burden compared with diabetic patients without DME. The substantial and enduring economic impact observed in real-world settings underscores the need to alleviate patients’ burden through preventive measures, effective management, appropriate reimbursement policies, and the development of innovative treatments. Strategies to mitigate the economic impact of DME should include proactive approaches such as expanding anti-VEGF reimbursement criteria, approving and reimbursing cost-effective drugs such as bevacizumab, advocating for proactive eye examinations, and embracing early diagnosis by ophthalmologists facilitated by cutting-edge methodologies such as artificial intelligence for patients with DM.


  • Open Access

    Analysis of Retinal Thickness in Patients with Chronic Diseases Using Standardized Optical Coherence Tomography Databases Based on the Radiology Common Data Model (R-CDM) (Preprint)

    by ChulHyoung Park, So Hee Lee, Rae Woong Park, Sang Jun Park, Seo Yoon Choi, Seng Chan You, Ja Young Jeon, Da Yeon Lee

    BACKGROUND The Observational Medical Outcome Partners - Common Data Model (OMOP-CDM) is an international standard for harmonizing electronic medical record (EMR) data. However, since it does not standardize unstructured data such as medical imaging, utilizing this data in multi-institutional collaborative research becomes challenging. To overcome this limitation, extensions such as the Radiology Common Data Model (R-CDM) have emerged to include and standardize these data types. OBJECTIVE This work aims to demonstrate that by standardizing Optical Coherence Tomography (OCT) data into an R-CDM format, multi-institutional collaborative studies analyzing changes in retinal thickness in patients with long-standing chronic diseases can be performed very efficiently. METHODS We standardized OCT images collected from two tertiary hospitals for research purposes using the R-CDM. As a proof of concept, we conducted a comparative analysis of retinal thickness between patients who have long suffered from chronic diseases and those who have not. Patients diagnosed or treated for retinal and choroidal diseases, which could affect retinal thickness, were excluded from the analysis. Using the existing OMOP-CDM at each institution, we extracted cohorts of chronic disease patients and control groups, performing large-scale 1:2 propensity score matching (PSM). Subsequently, we linked OMOP-CDM and R-CDM to extract the OCT image data of these cohorts and analyzed central macular thickness (CMT) and retinal nerve fiber layer (RNFL) thickness using a linear mixed model. RESULTS OCT data of 261,874 images from Ajou University Medical Center (AUMC) and 475,626 images from Seoul National University Bundang Hospital (SNUBH) were standardized in the form of R-CDM. The R-CDM databases established at each institution were linked with the OMOP-CDM database. Following 1:2 PSM, the type 2 diabetes mellitus (T2DM) cohort included 957 patients, and the control cohort had 1,603 patients. During the follow-up period, significant reductions in CMT were observed in the T2DM cohorts at both institutions (P = 0.04 and P < 0.01, respectively), without significant changes in RNFL thickness (P = 0.56 and P = 0.39, respectively). Notably, a significant reduction in CMT during the follow-up was observed only at AUMC in the hypertension (HTN) cohort, compared to the control group; no other significant differences in retinal thickness changes were found in the remaining analyses. CONCLUSIONS The significance of our study lies in demonstrating the efficiency of multi-institutional collaborative research that simultaneously utilizes clinical data and medical imaging data by leveraging the OMOP-CDM for standardizing EMR data, and the R-CDM for standardizing medical imaging data.

  • Open Access

    Patient-Centered Economic Burden of Diabetic Macular Edema: Retrospective Cohort Study (Preprint)

    by Kyungseon Choi, Sang Jun Park, Hyuna Yoon, Seoyoon Choi, Yongseok Mun, Seok Kim, Sooyoung Yoo, Se Joon Woo, Kyu Hyung Park, Junghyun Na, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Diabetic macular edema (DME), a leading cause of blindness, requires treatment with costly drugs, such as anti–vascular endothelial growth factor (VEGF) agents. The prolonged use of these effective but expensive drugs results in an incremental economic burden for patients with DME compared with those with diabetes mellitus (DM) without DME. However, there are no studies on the long-term patient-centered economic burden of DME after reimbursement for anti-VEGFs. Objective: This retrospective cohort study aims to estimate the 3-year patient-centered economic burden of DME compared with DM without DME, using the Common Data Model. Methods: We used medical data from 1,903,603 patients (2003-2020), transformed and validated using the Observational Medical Outcomes Partnership Common Data Model from Seoul National University Bundang Hospital. We defined the group with DME as patients aged >18 years with nonproliferative diabetic retinopathy and intravitreal anti-VEGF or steroid prescriptions. As control, we defined the group with DM without DME as patients aged >18 years with DM or diabetic retinopathy without intravitreal anti-VEGF or steroid prescriptions. Propensity score matching, performed using a regularized logistic regression with a Laplace prior, addressed selection bias. We estimated direct medical costs over 3 years categorized into total costs, reimbursement costs, nonreimbursement costs, out-of-pocket costs, and costs covered by insurance, as well as healthcare resource utilization. An exponential conditional model and a count model estimated unbiased incremental patient-centered economic burden using generalized linear models and a zero-inflation model. Results: In a cohort of 454 patients with DME matched with 1640 patients with DM, the economic burden of DME was significantly higher than that of DM, with total costs over 3 years being 2.09 (95% CI 1.78-2.47) times higher. Reimbursement costs were 1.89 (95% CI 1.57-2.28) times higher in the group with DME than with the group with DM, while nonreimbursement costs were 2.54 (95% CI 2.12-3.06) times higher. Out-of-pocket costs and costs covered by insurance were also higher by a factor of 2.11 (95% CI 1.58-2.59) and a factor of 2.01 (95% CI 1.85-2.42), respectively. Patients with DME had a significantly higher number of outpatient (1.87-fold) and inpatient (1.99-fold) visits compared with those with DM (P<.001 in all cases). Conclusions: Patients with DME experience a heightened economic burden compared with diabetic patients without DME. The substantial and enduring economic impact observed in real-world settings underscores the need to alleviate patients’ burden through preventive measures, effective management, appropriate reimbursement policies, and the development of innovative treatments. Strategies to mitigate the economic impact of DME should include proactive approaches such as expanding anti-VEGF reimbursement criteria, approving and reimbursing cost-effective drugs such as bevacizumab, advocating for proactive eye examinations, and embracing early diagnosis by ophthalmologists facilitated by cutting-edge methodologies such as artificial intelligence for patients with DM.